摘要
目的:评价国产美罗培南(倍能)降阶梯方案治疗老年社区获得性下呼吸道感染的疗效及安全性。方法:125例住院的中、重度老年社区获得性下呼吸道感染患者,随机分为降阶梯治疗组和对照组,比较两组的临床疗效、细菌清除率、感染控制天数、住院费用及不良反应。结果:治疗组共63例,痊愈36例,显效16例,总有效率82.5%,痰菌清除率78.24%,感染控制天数7.8±2.7天,均优于对照组,且副作用小;住院总费用比对照组明显低。结论:倍能用于老年重度下呼吸道感染降阶梯治疗的起始用药,疗效可靠,安全性好,并能降低总的住院费用。
Objective: To evaluate the stage rescue effects and the safety of domestic meropenem (PAINON) in the treatment of moderate and severe community-acquired lower respiratory tract infection in the elderly. Methods:Totally in-patient 125 elderly with moderate and severe community-acquired lower respiratory tract infection were randomized to two groups: stage rescue domestic meropenem group and control, the clinical efficacy, bacteriological eradication rate, the days of controlled infection, side-effect and total hospitalization cost were observed between two groups. Results= 63 cases were enrolled in meropenen group with an effective rate of 82.5%, bacteriological eradication rate of 78.24%, controlled infective days of 7.8 ± 2.7, and had less adverse reactions and total hospitalization cost, compared with the control. Conclusions: PAINON could be of first choice to treat severe lower respiratory tract infection in the elderly, and it is effective, safe and lower total hospitalization cost.
出处
《继续医学教育》
2006年第33期42-44,共3页
Continuing Medical Education